Treatment of severe hyaline membrane disease with surfactant (Curosurf). A collaborative clinical study.
We investigated the clinical efficacy of a new surfactant product, Curosurf, isolated from porcine lungs by liquid-gel chromatography. Ten premature newborn infants (birth weight 850-1850 g), all ventilated artificially for severe hyaline membrane disease categorized radiologically as stage III-IV, received a single dose of Curosurf (200 mg/kg) via the tracheal tube. This treatment resulted in a rapid improvement of oxygenation, similar to that observed by other teams collaborating in the study and, in an astonishingly fast resolution of the radiological changes. In comparison with a control group of 8 infants, the surfactant-treated babies also had a lower incidence of acute and chronic complications.
Büky
B
B
Second Department of Obstetrics and Gynecology, Semmelweis Medical University, Budapest, Hungary.
Dévai
G
G
Várady
E
E
Rózsavölgyi
A
A
Kovách
I
I
Kovács
A
A
Jancsó
G
G
Waldinger
K
K
Görgényi
A
A
Zsolnai
B
B
D001688:Biological Products; D005260:Female; D006801:Humans; D006819:Hyaline Membrane Disease / Q000000981:diagnostic imaging / Q000188:drug therapy*; D007231:Infant, Newborn; D008297:Male; D010743:Phospholipids; D011663:Pulmonary Surfactants / Q000627:therapeutic use*; D011859:Radiography
D001688:Biological Products; D010743:Phospholipids; D011663:Pulmonary Surfactants; C068291:poractant alfa